Relevant bibliographies by topics / Disease management / Journal articles

Journal articles on the topic 'Disease management'

To see the other types of publications on this topic, follow the link: Disease management.
Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Disease management.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jagota, Roma. "Homoeopathic Management of Meniere's Disease." International Journal of Science and Research (IJSR) 13, no. 7 (July 5, 2024): 895–96. http://dx.doi.org/10.21275/sr24717175319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zinkernagel, V., H. Hausladen, and H. Habermeyer. "Practical application of integrated disease management." Plant Protection Science 38, SI 1 - 6th Conf EFPP 2002 (January 1, 2002): 212–20. http://dx.doi.org/10.17221/10358-pps.

Full text
Abstract:
A decision support system for cereal diseases and late blight of potatoes has been developed at the Chair of Phytopathology,<br />Technische Universität München. The Wheat and Barley Prognosis System has been in use for many years by the<br />Bavarian official advisory service. It is based on an exact diagnosis and established biological thresholds influenced by<br />weather. Certain fungicides are recommended also covering diseases which have not reached the threshold. Diseases under<br />consideration are eye spot disease, powdery mildew, Septoria leaf blotch, Septoria leaf and glume blotch, tan spot, brown<br />and yellow rusts.The PhytophthoraModel Weihenstephan consists of two parts, weather based prognosis and monitoring in<br />the unsprayed control plots. Spraying recommendations are given based on the results of the above-mentioned parts and<br />considering cultivar behaviour and blight development in the field. The first spraying in the season as well as the timing<br />of the following ones are crucial. This model does not give any recommendations regarding which active ingredient should<br />applied. However there is a distinction made with regard to contact (protective) fungicides and systemic fungicides. The<br />PhytophthoraModel Weihenstephan has been in use for several years in Germany as well as in Austria.
APA, Harvard, Vancouver, ISO, and other styles
3

Kesteloot, Katrien. "DISEASE MANAGEMENT." International Journal of Technology Assessment in Health Care 15, no. 3 (July 1999): 506–19. http://dx.doi.org/10.1017/s0266462399015366.

Full text
Abstract:
Recently, many disease management programs, especially for patients with chronic diseases, have emerged. This paper discusses the potential benefits and disadvantages of disease management, on the basis of an extensive literature review. Disease management is an innovative technology in health care management, which is diffusing throughout the health care system without critical evaluation. Evidence on its effectiveness and costs is still very scarce, while the legal, ethical, organizational, and social implications of this practice have not been analyzed seriously. Before disease management is implemented on a broader scale in different European settings, first, empirical evidence about its alleged benefits and cost-effectiveness should be collected.
APA, Harvard, Vancouver, ISO, and other styles
4

Shabir, Morgan. "Cognitive impairment in Parkinson’s disease: Multidisciplinary Symposium Clinical Management of Parkinson’s disease." Neuroscience and Neurological Surgery 1, no. 3 (August 10, 2017): 01–03. http://dx.doi.org/10.31579/2578-8868/022.

Full text
Abstract:
People with Parkinson’s disease (PD) and their care partners frequently report cognitive decline as one of their greatest concerns. Mild cognitive impairment affects approximately 20–50% of people with PD, and longitudinal studies reveal dementia in up to 80% of PD. Through the Parkinson’s Disease Foundation Community Choice Research Award Program, the PD community identified maintaining cognitive function as one of their major unmet needs. In response, a working group of experts across multiple disciplines was organized to evaluate the unmet needs, current challenges, and future opportunities related to cognitive impairment in PD. Specific conference goals included defining the current state in the field and gaps regarding cognitive issues in PD from patient, care partner, and healthcare professional viewpoints; discussing non-pharmacological interventions to help maintain cognitive function; forming recommendations for what people with PD can do at all disease stages to maintain cognitive health; and proposing ideas for how healthcare professionals can approach cognitive changes in PD. This paper summarizes the discussions of the conference, first by addressing what is currently known about cognitive dysfunction in PD and discussing several non-pharmacological interventions that are often suggested to people with PD. Second, based on the conference discussions, we provide considerations for people with PD for maintaining cognitive health and for healthcare professionals and care partners when working with people with PD experiencing cognitive impairment. Furthermore, we highlight key issues and knowledge gaps that need to be addressed in order to advance research in cognition in PD and improve clinical care.
APA, Harvard, Vancouver, ISO, and other styles
5

N.I., Zakirova. "MANAGEMENT OF PREGNANT WOMEN WITH THYROID DISEASE." Frontline Medical Sciences and Pharmaceutical Journal 02, no. 03 (March 1, 2022): 122–27. http://dx.doi.org/10.37547/medical-fmspj-02-03-13.

Full text
Abstract:
The course of pregnancy, thyroid status, hormonal levels were studied in 96 women with autoimmune thyroiditis (AIT). It was found that pregnant women have a number of complications (54.8%) from the mother and the fetus, AIT has an unfavorable effect on the course of pregnancy, there is a high risk of miscarriage and termination of pregnancy, there is a decrease in the level of thyroid hormones and an increase in the level of TSH in comparison with similar indicators of healthy pregnant women. For the prevention of complications of gestation and prematurity of pregnancy in women with AIT, a planned determination of TSH blood from early gestation is recommended.
APA, Harvard, Vancouver, ISO, and other styles
6

Lazak, Fatima Zahae, and Redoune Moutj. "EPIDEMIOLOGICAL AND THERAPEUTIC PERSPECTIVES IN DISEASE MANAGEMENT." International Journal of Prevention Practice and Research 02, no. 03 (May 4, 2022): 01–05. http://dx.doi.org/10.55640/medscience-abcd614.

Full text
Abstract:
This paper explores the epidemiological landscape and therapeutic interventions related to a specific health concern. Epidemiological studies provide a comprehensive overview of the prevalence, incidence, risk factors, and patterns of this health issue across diverse populations. The discussion delves into the multifaceted nature of epidemiological research, elucidating the role of various factors—genetic, environmental, social, and behavioral—in influencing disease dynamics. Moreover, this paper analyzes therapeutic strategies, encompassing both traditional and innovative approaches, aiming to mitigate the burden of the health concern. Emphasis is placed on evidence-based interventions, advancements in treatment modalities, and their efficacy in improving patient outcomes. The synthesis of epidemiological data with therapeutic interventions forms a critical nexus in shaping public health policies, clinical practices, and future research directions, ultimately contributing to enhanced healthcare delivery and disease management. The interplay between epidemiology and therapeutics is critical in understanding and addressing the dynamics of diseases. Epidemiological studies elucidate the patterns, causes, and risk factors of diseases within populations, providing essential insights into disease transmission, prevalence, and impact. Concurrently, therapeutic interventions aim to alleviate, manage, or eradicate diseases through various modalities such as pharmaceuticals, lifestyle modifications, and behavioral interventions. This abstract explores the intricate relationship between epidemiology and therapeutics, emphasizing their roles in disease prevention, treatment strategies, and public health initiatives. Understanding the epidemiological landscape informs the development and implementation of effective therapeutic approaches, ultimately contributing to improved health outcomes and disease control within communities and globally
APA, Harvard, Vancouver, ISO, and other styles
7

Epstein, Robert S., and Margaret G. McGlynn. "Disease Management." Disease Management & Health Outcomes 1, no. 1 (January 1997): 3–10. http://dx.doi.org/10.2165/00115677-199701010-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Harris, John M. "Disease Management." Disease Management & Health Outcomes 1, no. 1 (January 1997): 11–16. http://dx.doi.org/10.2165/00115677-199701010-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Todd, Warren E., John H. Eichert, and Michael R. Toscani. "Disease Management." Disease Management & Health Outcomes 1, no. 1 (January 1997): 26–33. http://dx.doi.org/10.2165/00115677-199701010-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Disease Management." Disease Management & Health Outcomes 2, no. 5 (November 1997): 264. http://dx.doi.org/10.2165/00115677-199702050-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Todd, Warren E., and Edward H. Ladon. "Disease Management." Disease Management and Health Outcomes 3, no. 1 (1998): 1–10. http://dx.doi.org/10.2165/00115677-199803010-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Pleick, Stefanie, and Winfried Sennekamp. "Disease Management." Soziale Arbeit 60, no. 12 (2011): 448–54. http://dx.doi.org/10.5771/0490-1606-2011-12-448.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Bloor, Karen, and Alan Maynard. "Disease Management." PharmacoEconomics 17, no. 6 (June 2000): 539–44. http://dx.doi.org/10.2165/00019053-200017060-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

STAHL, DULCELINA A. "Disease Management." Nursing Management (Springhouse) 27, no. 11 (November 1996): 25???30. http://dx.doi.org/10.1097/00006247-199611000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Cameron, Amanda. "Disease management." PharmacoEconomics & Outcomes News 234, no. 1 (October 1999): 3–5. http://dx.doi.org/10.1007/bf03275189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Cameron, Amanda. "Disease management." PharmacoEconomics & Outcomes News 209, no. 1 (April 1999): 3–4. http://dx.doi.org/10.1007/bf03319508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Short, Robert. "Disease management." PharmacoEconomics & Outcomes News 46, no. 1 (January 1996): 3–4. http://dx.doi.org/10.1007/bf03269769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Owen, Mindy. "Disease management." Case Manager 15, no. 3 (May 2004): 45–47. http://dx.doi.org/10.1016/j.casemgr.2004.04.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Schmidlin-von Ziegler, Nicole I. "Disease Management." Medizinische Klinik 93, no. 1 (January 1998): 52–56. http://dx.doi.org/10.1007/bf03045043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Althaf, Shebin, Manoj Khanal, Anita Rawat, and Kishalay Datta. "Devic’s Disease: The Confusing CNS Disease." Indian Journal of Emergency Medicine 9, no. 3 (September 15, 2023): 107–9. http://dx.doi.org/10.21088/ijem.2395.311x.9323.10.

Full text
Abstract:
Neuromyelitis optica spectrum is order (NMOSD) is a rare auto-antibody mediated disease of the central nervous system involving the central nervous system. The symptoms should alert the clinician to the diagnosis. Prompt diagnosis in the emergency department plays a crucial role as delay in diagnosis and initiation of management will lead to increased chances of morbidity and mortality. Approximately 80% of NMO patients have auto-antibodies against aquaporin-4, a water channel expressed on astrocytes. In this case report, we discuss a patient with NMO disease, the diagnosis and its management.
APA, Harvard, Vancouver, ISO, and other styles
21

A. de Boer, E. A. M. Joosen, W. "Disease Management in Ulcer Disease." Scandinavian Journal of Gastroenterology 34, no. 230 (January 1999): 23–28. http://dx.doi.org/10.1080/003655299750025507.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Singh, R. K., Akhlak Husen, A. K. Chaudhary, and R. K. Maurya. "Clinical profile and management of benign breast disease." Asian Pacific Journal of Health Sciences 7, no. 1 (March 30, 2020): 81–85. http://dx.doi.org/10.21276/apjhs.2020.7.1.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Chanda, Ipsita. "COVID-19 Pandemic: Disease Management and Current Therapeutics." Journal of Communicable Diseases 52, no. 04 (December 31, 2020): 29–34. http://dx.doi.org/10.24321/0019.5138.202037.

Full text
Abstract:
The highly contagious disease COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic. The high rate of contact transmission of this virus is the major cause of concern nowadays. Owing to the absence of any effective drugs/vaccines against COVID-19, many countries adopted ‘lockdown’ to minimize transmission of virus. The other means that was applied during lockdown, to mitigate the growth of infection is the ‘test, trace, track and isolate’. However, different countries responded differently to these control measures with different outcome in the growth of infection. For now, several countries have started ‘unlock’, to handle the severe economic stress, created in response to lockdown. Again, lifting lockdown is another global threat, having the chance of second wave of infection. In such situation, the major challenge is to prevent the spread of infection, amid resumption of work. The present review is aimed to outline the prospect and future direction of disease management and current therapeutics against COVID-19.
APA, Harvard, Vancouver, ISO, and other styles
24

Goel, Amit, Vinod Kumar, Rahul Rohitaj, MD Najim, Vinod Kumar Singh, and P. K. Ganguly. "Management of Gastroesophageal Reflux Disease: A Prospective Study." New Indian Journal of Surgery 6, no. 2 (2019): 151–54. http://dx.doi.org/10.21088/nijs.0976.4747.10219.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

MS, Hafeza, and Vanitha Palanisamy. "Kimura Disease of the Parotid Gland: Management Approach." Journal of Clinical Otorhinolaryngology 4, no. 1 (January 4, 2022): 01–03. http://dx.doi.org/10.31579/2692-9562/038.

Full text
Abstract:
Here we present a 43-years old Malay man with Kimura’s disease of the right parotid gland. Asian men have a predisposition for this chronic inflammatory disorder of unknown etiology mostly presenting at the head and neck region. The management in dealing with this patient is not straight forward as the presentation mimics a subcutaneous tumor-like mass in which main differential diagnosis includes lymphoproliferative disorders and parotid neoplasm. Moreover, cytological investigation is inadequate, and this necessitates the use intra-operative frozen section prior to tumor debulking. Without proper investigation, misdiagnosis can occur and potentially expose the patient to unnecessary extensive surgical procedures. Here we discuss step by step approach in managing this patient.
APA, Harvard, Vancouver, ISO, and other styles
26

Somasundaram, Dr Deepa Subbiah, Dr Salim K. Ismail, Dr Firdous Jahan, Dr Ganji Shivalingam, and Dr Kallesh Hebbal. "Kawasaki Disease – Diagnosis and Management- A Retrospective Study." Saudi Journal of Medical and Pharmaceutical Sciences 2, no. 6 (June 2016): 149–55. http://dx.doi.org/10.21276/sjmps.2016.2.6.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Pimperkhede, Ms Dipali R., Mr Vaibhav, and G. Kute. "A Systemic Review on Management of Alzheimer’s Disease." International Journal of Research Publication and Reviews 4, no. 4 (April 23, 2023): 4637–45. http://dx.doi.org/10.55248/gengpi.4.423.38127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Golovach, I. Yu, and Ye D. Yehudina. "Perygravid management of rheumatic disease." HEALTH OF WOMAN, no. 2(148) (March 30, 2020): 42–51. http://dx.doi.org/10.15574/hw.2020.148.42.

Full text
Abstract:
Management of inflammatory rheumatic diseases in preconception period, pregnancy and breastfeeding has undergone significant changes over the past few years. Modern therapy, including biological and targeted synthetic disease modifying drugs, has significantly improved the control of rheumatic diseases, which has led to an increase in the patients’ number planning a pregnancy with serious diseases. When consulting such patients, it is necessary to discuss the possible time of conception (regarding the activity of the disease), the effect of the disease on pregnancy and pregnancy on the disease, as well as the potential need to change the regimen of medications during pregnancy and breastfeeding. This review summarizes information on the effects of pregnancy on various rheumatic diseases and vice versa, changes in therapy and monitoring of patients with rheumatic diseases before, during and after pregnancy. Women with inflammatory rheumatic diseases need advice on drug therapy before planning pregnancy, during pregnancy, and breastfeeding. Safe disease-modifying drugs that can be taken during pregnancy are hydroxychloroquine, sulfosalazine, azathioprine, and cyclosporine. Glucocorticoids and non-steroidal anti-inflammatory drugs can also be taken up to 32 weeks of gestation. Most inhibitors of tumor necrosis factor (anti-TNF) are also safe during pregnancy. During pregnancy, a clear monitoring of the activity of the disease is necessary, control of the level of autoantibodies, especially anti-SSA / Ro and anti-SSB / La and antiphospholipid antibodies, an assessment of the degree of organ dysfunction, especially kidney damage. Presented are modern approaches to optimizing the management of inflammatory rheumatic disease during pregnancy. For patients with inflammatory rheumatic diseases, a successful pregnancy outcome is optimized by creating an individual plan to suppress disease activity using a targeted approach. Key words: pregnancy, rheumatic diseases, treatment, lactation, management tactics, drugs.
APA, Harvard, Vancouver, ISO, and other styles
29

L., J. F. "DISEASE AND WELLNESS MANAGEMENT FIRMS!?" Pediatrics 96, no. 5 (November 1, 1995): A62. http://dx.doi.org/10.1542/peds.96.5.a62.

Full text
Abstract:
In 1993 Eli Lilly publicly announced that it was turning itself from a drug firm into a "disease-management" one. The idea is that rather than focusing a company on a specific part of the health-care market, such as drugs or hospitals, a firm should deal with all aspects of a disease. Chronic diseases that require lots of attention could produce the biggest savings (and hence profits). Eli Lilly has launched five disease-management programmes, for asthma, pulmonary disease, depression, diabetes, and ulcers. Several small firms are already thriving in "disease management"... The "wellness-management" school is led by KPMG and Andersen Consulting. They believe that the disease-management approach fails in several respects. Health care involves maintaining health as well as treating diseases; patients often suffer from several diseases, which cannot easily be isolated and managed separately; and "disease-management" is an unappealing notion for companies that want to associate themselves with health, not illness. Instead, companies that promote "wellness" should organize their product portfolios around groups of patients, trying to deal with all their medical needs. Some drug firms are doing this.
APA, Harvard, Vancouver, ISO, and other styles
30

Selecky, Christobel E. "Disease Management of Chronic Obstructive Pulmonary Disease from a Disease Management Organization Perspective." Disease Management & Health Outcomes 16, no. 5 (2008): 319–25. http://dx.doi.org/10.2165/0115677-200816050-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Deutman, Robert. "DISC DISEASE MANAGEMENT." Orthopedics 14, no. 4 (April 1991): 415. http://dx.doi.org/10.3928/0147-7447-19910401-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

&NA;. "Disease Management Programmes." Disease Management & Health Outcomes 2, no. 2 (August 1997): 108. http://dx.doi.org/10.2165/00115677-199702020-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Calhoun, Janet, and Henriette Coetzer. "Respiratory Disease Management." Disease Management and Health Outcomes 9, Supplement 1 (2001): 21–27. http://dx.doi.org/10.2165/00115677-200109001-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

&NA;. "Disease Management Update." Disease Management and Health Outcomes 10, no. 1 (2002): 71–73. http://dx.doi.org/10.2165/00115677-200210010-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

&NA;. "Disease Management Update." Disease Management and Health Outcomes 10, no. 2 (2002): 137–40. http://dx.doi.org/10.2165/00115677-200210020-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

&NA;. "Disease Management Update." Disease Management and Health Outcomes 10, no. 3 (2002): 201–4. http://dx.doi.org/10.2165/00115677-200210030-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

&NA;. "Disease Management Update." Disease Management and Health Outcomes 10, no. 4 (2002): 263–67. http://dx.doi.org/10.2165/00115677-200210040-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

&NA;. "Disease Management Update." Disease Management and Health Outcomes 10, no. 5 (2002): 327–31. http://dx.doi.org/10.2165/00115677-200210050-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 6 (2002): 385–94. http://dx.doi.org/10.2165/00115677-200210060-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 7 (2002): 453–60. http://dx.doi.org/10.2165/00115677-200210070-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Shelton, Paul S. "Disease Management Programs." Disease Management & Health Outcomes 10, no. 8 (2002): 461–67. http://dx.doi.org/10.2165/00115677-200210080-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 8 (2002): 515–25. http://dx.doi.org/10.2165/00115677-200210080-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 9 (2002): 589–600. http://dx.doi.org/10.2165/00115677-200210090-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 10 (2002): 661–72. http://dx.doi.org/10.2165/00115677-200210100-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 11 (2002): 731–39. http://dx.doi.org/10.2165/00115677-200210110-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

&NA;. "Disease Management Update." Disease Management & Health Outcomes 10, no. 12 (2002): 811–18. http://dx.doi.org/10.2165/00115677-200210120-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

&NA;. "Disease Management Update." Disease Management & Health Outcomes 11, no. 1 (2003): 61–70. http://dx.doi.org/10.2165/00115677-200311010-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

&NA;. "Disease Management Update." Disease Management & Health Outcomes 11, no. 2 (2003): 129–37. http://dx.doi.org/10.2165/00115677-200311020-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

&NA;. "Disease Management Update." Disease Management & Health Outcomes 11, no. 3 (2003): 197–207. http://dx.doi.org/10.2165/00115677-200311030-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

&NA;. "Disease Management Update." Disease Management & Health Outcomes 11, no. 4 (2003): 271–76. http://dx.doi.org/10.2165/00115677-200311040-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Disease management' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography